

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A method of delivering one or more IRM compounds to a tissue in a subject, the method comprising administering an IRM preparation to the subject, wherein the IRM preparation comprises a soluble IRM-polymer complex comprising one or more IRM compounds attached to a polymer.
2. (Original) A method of delivering one or more IRM compounds to a tissue in a subject, the method comprising administering an IRM preparation to the subject, wherein the IRM preparation comprises a soluble IRM-polymer complex comprising one or more IRM compounds attached to a soluble polymer comprising alkylene oxide moieties, wherein the IRM-polymer complex has a molecular weight of 1 kDa to 500 kDa.
3. (Canceled)
4. (Currently Amended) The method of claim 1 ~~or claim 2~~ wherein the soluble IRM-polymer complex has a solubility of at least 0.1 microgram per milliliter in water under physiological conditions.
5. (Canceled)
6. (Currently Amended) The method of ~~any one of claims 1 through 5~~ wherein one or more IRM compounds are covalently attached to a soluble polymer.
- 7.-13. (Canceled)

14. (Currently Amended) The method of claim 13 wherein the ~~localized tissue region~~ is a tumor.

15. (Currently Amended) The method of claim 14 wherein the ~~localized tissue region~~ tumor is a breast cancer tumor, a stomach cancer tumor, a lung cancer tumor, a head or neck cancer tumor, a colorectal cancer tumor, a renal cell carcinoma tumor, a pancreatic cancer tumor, a basal cell carcinoma tumor, a cervical cancer tumor, a melanoma cancer tumor, a prostate cancer tumor, an ovarian cancer tumor, or a bladder cancer tumor.

16. (Canceled)

17. (Currently Amended) The method of claim 1 ~~or any one of claims 3 through 16 except as dependent on claim 2~~ wherein the polymer comprises alkylene oxide moieties.

18. (Currently Amended) The method ~~of any one of claims 1 through 17~~ wherein the IRM is an agonist of at least one TLR selected from the group consisting of TLR7 and TLR8.

19.-26. (Canceled)

27. (Currently Amended) The method ~~of any one of claims 1 through 25~~ wherein the IRM compound is selected from the group consisting of imidazoquinoline amines; tetrahydroimidazoquinoline amines; and imidazopyridine amines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines; tetrahydroimidazonaphthyridine amines; oxazoloquinoline amines; thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolonaphthyridine amines; thiazolonaphthyridine amines; 1*H*-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines; and combinations thereof.

28. (Currently Amended) The method of ~~any one of claims 1 through 25~~ wherein the IRM compound is selected from the group consisting of purines, imidazoquinoline amides, benzimidazoles, 1*H*-imidazopyridines, adenines, and derivatives thereof.

29.-31. (Canceled)

32. (Currently Amended) The method of claim 1 ~~or any one of claims 3 through 31 except as dependent on claim 2~~ wherein the polymer is a soluble polymer selected from the group consisting of poly(alkylene glycols), poly(olefinic alcohols), polyvinylpyrrolidones, poly(hydroxyalkylmethacrylamides), poly(hydroxyalkylmethacrylates), polyvinyl alcohols, polyoxazolines, poly(acrylic acids), polyacrylamides, polyglutamates, polylysines, polysaccharides, and combinations thereof.

33. (Original) A soluble IRM-polymer complex comprising one or more IRM compounds attached to an alkylene oxide-containing polymer.

34.-39. (Canceled)

40. (Currently Amended) The soluble IRM-polymer complex ~~of any one of claims 33 through 36~~ wherein the soluble IRM-polymer complex has a solubility of at least 0.1 microgram per milliliter in water under physiological conditions.

41. (Canceled)

42. (Currently Amended) The soluble IRM-polymer complex ~~of any one of claims 33 through 41~~ wherein the IRM-polymer complex has a molecular weight of 1 kDa to 500 kDa.

43. (Canceled)

44. (Canceled)

45. (Currently Amended) The soluble IRM-polymer complex of claim 42 wherein the IRM-polymer complex has a molecular weight of 20 kDa to 200 kDa.

46. (Canceled)

47. (Currently Amended) The soluble IRM-polymer complex of any one of claims 33 through 46 wherein the one or more IRM compounds are covalently attached to an alkylene oxide-containing polymer.

48. (Currently Amended) The soluble IRM-polymer complex of claim 42 or any one of claims 36 through 46 except as dependent on claim 33 wherein the soluble polymer is selected from the group consisting of poly(alkylene glycols), poly(olefinic alcohols), polyvinylpyrrolidones, poly(hydroxyalkylmethacrylamides), poly(hydroxyalkylmethacrylates), polyvinyl alcohols, polyoxazolines, poly(acrylic acids), polyacrylamides, polyglutamates, polylysines, polysaccharides and combinations thereof.

49.-52. (Canceled)